MetLife Investment Management LLC Buys New Shares in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

MetLife Investment Management LLC bought a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULCGet Rating) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 18,890 shares of the company’s stock, valued at approximately $153,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Rhumbline Advisers boosted its position in Fulcrum Therapeutics by 7.6% during the first quarter. Rhumbline Advisers now owns 34,115 shares of the company’s stock valued at $807,000 after buying an additional 2,408 shares during the period. BlackRock Inc. boosted its position in Fulcrum Therapeutics by 0.9% during the first quarter. BlackRock Inc. now owns 2,228,610 shares of the company’s stock valued at $52,707,000 after buying an additional 20,532 shares during the period. Dimensional Fund Advisors LP boosted its position in Fulcrum Therapeutics by 50.8% during the first quarter. Dimensional Fund Advisors LP now owns 282,793 shares of the company’s stock valued at $6,688,000 after buying an additional 95,272 shares during the period. Lord Abbett & CO. LLC boosted its position in Fulcrum Therapeutics by 1.8% during the first quarter. Lord Abbett & CO. LLC now owns 188,651 shares of the company’s stock valued at $4,462,000 after buying an additional 3,417 shares during the period. Finally, Vanguard Group Inc. boosted its position in Fulcrum Therapeutics by 2.4% during the first quarter. Vanguard Group Inc. now owns 1,503,821 shares of the company’s stock valued at $35,565,000 after buying an additional 35,162 shares during the period.

Insiders Place Their Bets

In other Fulcrum Therapeutics news, CEO Robert J. Gould sold 6,766 shares of the firm’s stock in a transaction dated Friday, January 13th. The shares were sold at an average price of $15.00, for a total value of $101,490.00. Following the completion of the sale, the chief executive officer now directly owns 499,864 shares in the company, valued at $7,497,960. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Fulcrum Therapeutics news, CEO Robert J. Gould sold 6,766 shares of the firm’s stock in a transaction dated Friday, January 13th. The shares were sold at an average price of $15.00, for a total value of $101,490.00. Following the completion of the sale, the chief executive officer now directly owns 499,864 shares in the company, valued at $7,497,960. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Ra Capital Management, L.P. acquired 1,341,420 shares of the stock in a transaction on Friday, December 16th. The stock was bought at an average price of $5.42 per share, with a total value of $7,270,496.40. Following the completion of the acquisition, the insider now directly owns 9,403,049 shares of the company’s stock, valued at $50,964,525.58. The disclosure for this purchase can be found here. Insiders purchased 4,372,675 shares of company stock worth $38,695,655 over the last three months. Company insiders own 14.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on FULC. Oppenheimer cut their price target on shares of Fulcrum Therapeutics from $26.00 to $20.00 and set an “outperform” rating for the company in a research report on Monday, February 27th. Bank of America lowered shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating in a research report on Friday, February 24th. The Goldman Sachs Group increased their target price on shares of Fulcrum Therapeutics from $11.00 to $17.00 and gave the stock a “buy” rating in a report on Thursday, January 19th. Piper Sandler increased their target price on shares of Fulcrum Therapeutics from $18.00 to $21.00 and gave the stock an “overweight” rating in a report on Monday, January 23rd. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Fulcrum Therapeutics in a report on Tuesday, February 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.86.

Fulcrum Therapeutics Price Performance

Shares of FULC opened at $5.99 on Monday. Fulcrum Therapeutics, Inc. has a one year low of $3.21 and a one year high of $24.79. The company has a 50-day simple moving average of $10.86 and a two-hundred day simple moving average of $8.40. The firm has a market capitalization of $311.78 million, a PE ratio of -2.34 and a beta of 2.25.

About Fulcrum Therapeutics

(Get Rating)

Fulcrum Therapeutics, Inc is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T.

Featured Stories

Institutional Ownership by Quarter for Fulcrum Therapeutics (NASDAQ:FULC)

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.